Clinical Discussion Series

Back to Basics: Tenets of Testing in Myeloma Diagnostics
Back to Basics: Tenets of Testing in Myeloma Diagnostics
CME, CPE, CNE
Thomas G. Martin III, MD
Release Date: December 20, 2016
Expiration Date: December 20, 2017

Reviewed: January 17, 2017 for clinical relevance; CE is expired.

The diagnostic and prognostic landscape for myeloma has evolved greatly with the introduction of new criteria per the International Myeloma Working Group, and ongoing research to better define smoldering and active myeloma. In this activity, Dr. Thomas Martin will provide a review of the updated diagnostic criteria, implementation of the Revised International Staging System (R-ISS) in practice, and clinical pearls to reinforce the basics of testing in the diagnosis of myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Celgene Corporation, and Takeda Oncology.
Begin, Earn Credit
 
Selecting Patients for Maintenance or Continuous Therapy Including Regimen Selection and Duration of Treatment
Selecting Patients for Maintenance or Continuous Therapy Including Regimen Selection and Duration of Treatment
CME, CPE
Philip McCarthy, MD
Release Date: October 07, 2015
Expiration Date: October 07, 2016

Reviewed: January 17, 2017 for clinical relevance; CE is expired.

Join team Managing Myeloma world expert Philip McCarthy, MD, professor of oncology and the director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York, as he reviews Managing Myeloma member responses to a recent survey regarding use of maintenance therapy in their practice. As part of Dr. McCarthy’s discussion, he provides an overview of current clinical data supporting specific maintenance strategy approaches after transplant, continuous therapy in non-transplant patients, as well as safety considerations. He also discusses some new approaches that are emerging from clinical trials. 

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
View Only, CE Expired